Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Fig. 4

Long-term dynamic changes in the percentage of dyslipidemia over 144 weeks after initial ART with TDF plus 3TC plus EFV in treatment-naive patients with HIV (n = 61). A The percentage of hypercholesterolemia (TC > 5.18 mmol/L). B The percentage of hyper low-density lipoprotein cholesterolemia (LDL-c > 3.37 mmol/L). C The percentage of hypo-high-density lipoprotein cholesterolemia (HDL-c < 1.00 mmol/L). D the percentage of hypertriglyceridemia (TG > 1.7 mmol/L). ART, active antiretroviral therapy. TDF, Tenofovir. 3TC, Lamivudine. EFV, Efavirenz. TC, total cholesterol. LDL-c, low-density lipoprotein cholesterol. HDL-c, high-density lipoprotein cholesterol. TG, triglyceride. The Kruskal-Wallis H(K) test for K independent samples was used to compare the percentage of dyslipidemia from baseline to 144 weeks. The Mann-Whitney test for two independent samples was used to compare the percentage of dyslipidemia between baseline and follow-up time points. Comparison between different time points and compared with baseline, *P < 0.05, ** P < 0.01, ***P < 0.001

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us